Stock Rating Upgrade
In the last week the Value Trend Rating for Vertex Pharmaceuticals Inc (NASDAQ: VRTX) improved from C to B reflecting improving fundamentals and high Appreciation Potential.
Recent Price Action
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) stock rose modestly by 0.5% on 8/9/24. The stock closed at $468.45. However, unusually low trading volume at 65% of normal accompanied the advance. The stock has been exceptionally strong relative to the market over the last nine months but has declined -7.4% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, VRTX is expected to continue to be an important Value Builder.
Vertex Pharmaceuticals has a current Value Trend Rating of B (Positive). This VT Rating improved in recent days from C previously. With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. Vertex Pharmaceuticals has a neutral Appreciation Score of 47 but a good Power Rating of 77, resulting in the Positive Value Trend Rating.
Be the first to comment